4basebio Plc Director/PDMR Shareholding

 
TIDM4BB 
 
13 July 2022 
 
                                 4basebio plc 
                                (the "Company") 
 
 
                              Director's Dealing 
 
4basebio PLC (AIM: 4BB), the specialist life sciences group focused on 
exploiting intellectual property in the field of cell and gene therapies and 
DNA vaccines, announces that it was notified on 12 July 2022 that Dr Heikki 
Lanckriet, chief executive officer, on the same day transferred 29,000 ordinary 
shares at a price of 415 pence per share from his personal holding into his 
SIPP (the "Transfer"). 
 
Following the Transfer, there is no change to Dr Heikki Lanckriet's beneficial 
holding, and his interest in the Company remains at 1,252,453 Ordinary Shares, 
representing approximately 10.17% of the Company's issued share capital. 
 
This announcement contains inside information for the purposes of Article 7 of 
EU Regulation 596/2014. 
 
For further enquiries, please contact: 
 
4basebio plc                                            [phone] 
 
Heikki Lanckriet, CEO 
 
Cairn Financial Advisers LLP (Nominated                 [phone] 
Adviser) 
 
Jo Turner / Sandy Jamieson 
 
finnCap Ltd (Broker)                                    [phone] 
 
Geoff Nash/Richard Chambers/Charlotte 
Sutcliffe 
 
 
 
 
Notification of a Transaction pursuant to Article 19(1) of Regulation (EU) No. 
596/2014 
 
1      Details of the person discharging managerial responsibilities/person closely 
       associated 
 
a.     Name                 Dr Heikki Lanckriet 
 
2      Reason for 
       notification 
 
a.     Position/Status      Chief Executive Officer 
 
b.     Initial notification Initial Notification 
       / 
       Amendment 
 
3      Details of the issuer, emission allowance market participant, auction 
       platform, auctioneer or auction monitor 
 
a.     Name                 4basebio plc 
 
b.     LEI                  213800E2DX9EAIUNCB30 
 
4      Details of the transaction(s): section to be repeated for (i) each type of 
       instrument; (ii) each type of transaction; (iii) each date; and (iv) each 
       place where transactions have been conducted 
 
a.     Description of the   Ordinary shares 
       financial 
       instrument, type of 
       instrument           ISIN: GB00BMCLYF79 
 
       Identification Code 
 
b.     Nature of the        Transfer from nominee account to SIPP 
       transaction 
 
c.     Price(s) and volume       Price(s) per      Volume(s) 
       (s)                       share (p) 
 
                                 415p              29,000 
 
d.     Aggregated             * 29,000 
       information            * 415 pence per share 
 
e.     Date of the          12/07/2022 
       transaction 
 
f.     Place of the         London Stock Exchange, AIM 
       transaction 
 
 
 
END 
 
 

(END) Dow Jones Newswires

July 13, 2022 02:00 ET (06:00 GMT)